Tg Therapeutics Inc (TGTX)

Relapsing Multiple Sclerosis · registered primary completion 2026-10-31 · NCT07211633

Published 2026-09-02Market cap $8,256M7 sourced statements

A Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety, Radiological and Clinical Effects of Subcutaneous Ublituximab in Participants With Relapsing Multiple Sclerosis (RMS) · PHASE3 · n=360 · active not recruiting

Share count and dilution

fact

$16M of convertible notes outstanding. Conversion price $1,125.00 against a share price near $55.43 — 20.3x above the current price.

Source: 10-Q filed 2026-08-05

“uded within long-term investments on the condensed consolidated balance sheet as of June 30, 2026 . The Company has $ 15.5 million aggregate principal amount of 5 % convertible notes outstanding, which are convertible at the option of the holder into common stock at a conversion price of $ 1,125 per share. The Company does not have a cash repayment obligation associated with these notes. The notes are classified with…”

fact

153,069,053 shares outstanding against 168,580,620 if every outstanding option, warrant and convertible were exercised. In that case 9.2% of a gain in enterprise value would accrue to those holders rather than to current shareholders.

Source: antidilutive-securities disclosure, 10-Q filed 2026-08-05

Market

fact

No approved product carries Relapsing Multiple Sclerosis on label.

Source: FDA label index

Trial registry

fact

Registered design for NCT07211633: randomized, open-label, 360 participants (estimated). Primary outcome: Area Under the Curve From Week 0 to Week 24 (AUC0-W24) of Ublituximab.

Source: ClinicalTrials.gov record

Regulatory

fact

Designations disclosed: Breakthrough Therapy, Fast Track, Orphan Drug, Priority Review Voucher. These accelerate review and, for Orphan, confer exclusivity if approved; none is evidence of efficacy.

Source: 10-Q filed 2026-08-05

Pipeline

fact

3 distinct molecules in 8 active company-sponsored trials; Ublituximab accounts for 9 of them at Phase 2/Phase 3.

Source: ClinicalTrials.gov, company as lead sponsor

Ownership and proceedings

fact

Directors and executive officers as a group hold 8.87%.

Source: DEF 14A filed 2026-04-30

Don't see a name? Request a sheet. Any US-listed biotech with a Phase 3 or a pending FDA decision — it gets built the same way, from the filings.

This sheet is dated and will not be edited. When the registered primary completion passes, its outcome is recorded on the scoreboard and a new dated sheet is published if the filings change materially.